Table 3.
Spearman’s correlation analysis of relative change in antibody levels in relation to DAS28 change in recent‐onset RA patients (n = 231)
| ACPA IgG | ACPA IgA | ACPA IgM | ACPA SIgA | |||||
|---|---|---|---|---|---|---|---|---|
| Months after inclusion | Rho | P | Rho | P | Rho | P | Rho | P |
| 0–3 | 0·242 | 0·003 | 0·260 | 0·008 | 0·457 | 0·001 | 0·402 | 0·001 |
| 3–12 | 0·271 | 0·001 | 0·171 | 0·079 | 0·276 | 0·021 | 0·240 | 0·036 |
| 12–36 | 0·232 | 0·003 | 0·056 | 0·555 | 0·210 | 0·069 | 0·018 | 0·875 |
DAS28 = disease activity score 28; ACPA = anti‐citrullinated protein antibodies; Ig = immunoglobulin; SIgA = secretory IgA.
Bold values display statistically significant differences.